Pulmonx Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmonx Corporation on April 2, 2024. The filing reports the appointment of a new Chief Financial Officer (CFO) and the concurrent resignation of the Interim CFO. The company is a Delaware corporation with its principal executive offices in Redwood City, California, and its common stock trades on the Nasdaq Global Select Market under the symbol "LUNG".
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the leadership transition in the finance department:
- Appointment: Mehul Joshi was appointed as Chief Financial Officer and Principal Financial and Accounting Officer, effective April 3, 2024.
- Resignation: John McKune resigned as Interim CFO on the effective date, returning to his prior role as Vice President of Finance and Corporate Controller.
Management Commentary, Compensation, and Risks
The filing details the compensatory arrangements for Mr. Joshi, which include:
- Base Salary: $450,000 annually.
- Target Bonus: 50% of the annual base salary.
- Sign-on Bonus: $200,000, subject to clawback provisions if employment terminates within two years for specific reasons.
- Equity Grants: A non-statutory stock option valued at $1,375,000 and a restricted stock unit (RSU) award valued at $1,350,000. Both vest over four years and were granted as an inducement material to employment.
- Severance: Eligibility for the company's severance and change in control plan, providing up to 12 months of base salary and 100% of the target bonus in the event of a change in control followed by termination without cause or resignation for good reason.
Mr. Joshi brings extensive experience from PhenomeX Inc. (formerly Berkeley Lights), ResMed Inc., and Gilead Sciences, Inc.
Investor Verification Checklist
- Verify the vesting schedule and performance conditions of the $2.725 million in total initial equity grants.
- Review the specific definitions of "Cause" and "Good Reason" in the Offer Letter to understand severance triggers.
- Confirm the impact of the leadership change on the company's upcoming financial reporting cycle.
- Check for any related party transactions or family relationships disclosed in the filing (none were reported).